newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line